- Value of obtaining early feedback from Key Opinion Leaders and Regulators
- Risk assessment at the trial level
- Trial oversight matrix implemented with all vendors and subcontractors
- Assessing outcomes from over 70 interviews with life science industry pioneers
- Reviewing what clinical professionals wish would be different in the life sciences industry
- Suggesting next steps towards further evolving clinical trials
- Reviewing current state and future direction of decentralized clinical trials post-COVID-19 through sponsor survey results
- Providing greater understanding of innovative modern solutions that could help support more effective patient engagement and choice
- Discussing best practices and barriers experienced when implementing DCT elements as part of global trials
- Sharing learnings to inform of modern patient centric ways of working for industry and regulators and available tools to support this
- Creating an efficient governance structure to suit the study
- Communicating and monitoring the framework
- Evaluating needs and wants of both sponsor and vendor companies
- Sharing best practice for governance oversight
- Emerging demands, flexibility and scalability in clinical supply chains
- Integration of advanced technologies: AI, machine learning, and IoT for better tracking and efficiency
- Assessing opportunities for incorporating sustainability practices and reducing carbon footprint
- Enhanced collaboration and fostering stronger partnerships between sponsors and CDMOs
- Data-driven decision-making: utilizing big data analytics for supply chain optimization
